Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19

被引：32
作者：
Ami, Ei-ichi [1 ]
Ohrui, Hiroshi [2 ]
机构：
[1] Kaken Pharmaceut Co Ltd, Med Affairs Div, Toshima Ku, Tokyo 1710033, Japan
[2] Yokohama Univ Pharm, Res Ctr Med Chem, Yokohama, Kanagawa 2450066, Japan
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2021年 / 12卷 / 04期
关键词：
COVID-19; DNA virus; RNA virus; RNA polymerase inhibitor; antiviral modified nucleoside; REVERSE-TRANSCRIPTASE; VIRUS-REPLICATION; POTENT; INHIBITOR; MECHANISM; T-705; DRUG; 5-FLUOROURACIL; SORIVUDINE; DESIGN;
D O I：
10.1021/acsmedchemlett.1c00070
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Great pioneers of nucleic acid chemistry had elucidated nucleic acid functions and structures and developed various antiviral modified nucleoside drugs. It is possible in theory that antiviral modified nucleosides prevent viral replication by inhibiting viral polymerases. However, biological phenomena far exceed our predictions at times. We describe the characteristics of the approved antiviral modified nucleosides from an organic chemistry perspective. Also, based on our experiences and findings through the development of the HIV-1 reverse-transcriptase inhibitor "Islatravir", we provide the practical and approximate guidelines for the drug development of antiviral modified nucleosides against COVID-19.
引用
收藏
页码：510 / 517
页数：8
相关论文
共 33 条
[1]  
[Anonymous], COMMUNICATION
[2]  
Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]
[3]   Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs [J].
Carroll, SS ;
Tomassini, JE ;
Bosserman, M ;
Getty, K ;
Stahlhut, MW ;
Eldrup, AB ;
Bhat, B ;
Hall, D ;
Simcoe, AL ;
LaFemina, R ;
Rutkowski, CA ;
Wolanski, B ;
Yang, ZC ;
Migliaccio, G ;
De Francesco, R ;
Kuo, LC ;
MacCoss, M ;
Olsen, DB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (14) :11979-11984
[4]   Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication [J].
Clark, JL ;
Hollecker, L ;
Mason, JC ;
Stuyver, LJ ;
Tharnish, PM ;
Lostia, S ;
McBrayer, TR ;
Schinazi, RF ;
Watanabe, KA ;
Otto, MJ ;
Furman, PA ;
Stec, WJ ;
Patterson, SE ;
Pankiewiez, KW .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (17) :5504-5508
[5]   Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets [J].
Cox, Robert M. ;
Wolf, Josef D. ;
Plemper, Richard K. .
NATURE MICROBIOLOGY, 2021, 6 (01) :11-+
[6]   Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase [J].
Diasio, RB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) :1-4
[7]   Structure-activity relationship of heterobase-modified 2′-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication [J].
Eldrup, AB ;
Prhavc, M ;
Brooks, J ;
Bhat, B ;
Prakash, TP ;
Song, QL ;
Bera, S ;
Bhat, N ;
Dande, P ;
Cook, PD ;
Bennett, CF ;
Carroll, SS ;
Ball, RG ;
Bosserman, M ;
Burlein, C ;
Colwell, LF ;
Fay, JF ;
Flores, OA ;
Getty, K ;
LaFemina, RL ;
Leone, J ;
MacCoss, M ;
McMasters, DR ;
Tomassini, JE ;
Von Langen, D ;
Wolanski, B ;
Olsen, DB .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (21) :5284-5297
[8]   SELECTIVITY OF ACTION OF AN ANTI-HERPETIC AGENT, 9-(2-HYDROXYETHOXYMETHYL)GUANINE [J].
ELION, GB ;
FURMAN, PA ;
FYFE, JA ;
DEMIRANDA, P ;
BEAUCHAMP, L ;
SCHAEFFER, HJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (12) :5716-5720
[9]   Synthesis of EFdA via a Diastereoselective Aldol Reaction of a Protected 3-Keto Furanose [J].
Fukuyama, Kei ;
Ohrui, Hiroshi ;
Kuwahara, Shigefumi .
ORGANIC LETTERS, 2015, 17 (04) :828-831
[10]   Mechanism of action of T-705 against influenza virus [J].
Furuta, Y ;
Takahashi, K ;
Kuno-Maekawa, M ;
Sangawa, H ;
Uehara, S ;
Kozaki, K ;
Nomura, N ;
Egawa, H ;
Shiraki, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :981-986
1234